Global supply chains in life sciences are facing increased scrutiny—and new legislation in the United States is accelerating that shift.
The proposed BIOSECURE Act is expected to significantly impact how pharmaceutical and biotechnology companies source materials, select partners, and manage global operations. As geopolitical concerns intersect with healthcare and national security, regulators and lawmakers are placing greater emphasis on supply chain transparency and control.
In 2026, organizations should be preparing for stricter oversight of foreign partnerships and increased pressure to reassess supplier networks.
Why the BIOSECURE Act Is Gaining Attention
The BIOSECURE Act is designed to limit U.S. government-funded entities from working with certain foreign biotechnology companies identified as potential national security risks.
While the legislation is still evolving, its implications extend beyond government contracts. Many organizations anticipate broader industry impact, including:
- Increased due diligence requirements for suppliers and partners
- Greater scrutiny of contract manufacturing organizations (CMOs/CDMOs)
- Pressure to reshore or diversify supply chains
- Enhanced documentation of sourcing and vendor qualification
This reflects a broader trend toward supply chain resilience and regulatory accountability in life sciences.
How This Affects Pharma and Biotech Companies
Pharmaceutical and biotech companies rely heavily on global supply chains for raw materials, manufacturing, and development support. Any disruption—or restriction—can have significant operational and regulatory consequences.
If enacted and enforced broadly, the BIOSECURE Act could require companies to:
- Reevaluate relationships with certain international partners
- Transition manufacturing or development activities to approved regions
- Strengthen supplier qualification and auditing processes
- Update risk management frameworks to address geopolitical exposure
These changes may impact timelines, costs, and overall operational strategy.
Regulatory and Compliance Considerations
From a regulatory perspective, changes in suppliers or manufacturing locations are not simple operational decisions—they require structured oversight and, in many cases, regulatory notification or approval.
Organizations must consider:
- Change control requirements under quality systems
- Comparability assessments for materials or processes
- Updates to regulatory filings and documentation
- Ongoing compliance with FDA and global regulatory expectations
Failure to properly manage these transitions can lead to compliance risks, inspection findings, or delays in product availability.
The Shift Toward Supply Chain Transparency
The BIOSECURE Act reinforces a growing expectation: organizations must have full visibility and control over their supply chains.
Regulators increasingly expect companies to understand not only their direct suppliers, but also upstream dependencies. This includes clear documentation of sourcing, manufacturing processes, and quality controls across all partners.
Transparency is no longer optional—it is becoming a regulatory expectation.
How to Prepare for Potential Impact
To prepare for evolving legislation and regulatory expectations, organizations should begin assessing their current supply chain risk and identifying potential vulnerabilities.
Key actions include strengthening supplier qualification programs, enhancing documentation and traceability, conducting risk assessments on global partnerships, and developing contingency plans for critical materials and services.
Proactive planning allows organizations to adapt more effectively as regulatory requirements continue to evolve.
How EMMA International Supports Supply Chain and Regulatory Strategy
At EMMA International, we support organizations in navigating complex regulatory and operational challenges, including supply chain transformation and compliance strategy.
Our teams help assess supplier risk, support change control and regulatory submissions, and design quality systems that maintain compliance during transitions.
As global supply chains face increasing scrutiny, organizations that take a proactive, structured approach will be best positioned to maintain continuity and regulatory confidence.
References
U.S. Congress. BIOSECURE Act (Proposed Legislation).
U.S. Food and Drug Administration. Supply Chain Integrity and Drug Shortage Prevention Guidance.
International Society for Pharmaceutical Engineering (ISPE). Global Supply Chain Risk Management Guidance.
